123I-2-iodo-tyrosine, a new tumour imaging agent: Human biodistribution, dosimetry and initial clinical evaluation in glioma patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 7, 2007, Pages 994-1002

  Keyaerts, Marleen ^a,b   Lahoutte, Tony ^a,b   Neyns, Bart ^a   Caveliers, Vicky ^a,b   Vanhove, Chris ^a,b   Everaert, Hendrik ^a   Kersemans, Ken ^a   Franken, Philippe R ^a,b   Mertens, John ^a   Bossuyt, Axel ^a,b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

123I 2IT; Amino acid tracer; Biodistribution; Glioma

Indexed keywords

2 IODOTYROSINE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2 IODOTYROSINE; 2-IODOTYROSINE; DIAGNOSTIC AGENT; IODOTYROSINE;

ADULT; AGED; ARTICLE; BLADDER; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER PROGRAM; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DOSE CALCULATION; DOSIMETRY; FEMALE; FOLLOW UP; GLIOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGING; KIDNEY CLEARANCE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; QUANTITATIVE ANALYSIS; RADIATION NECROSIS; RECURRENT DISEASE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL INTESTINE; TUMOR DIAGNOSIS; URINALYSIS; WHOLE BODY SCINTISCANNING; ADOLESCENT; ANTIBODY SPECIFICITY; BODY BURDEN; BRAIN TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; PILOT STUDY; RADIATION DOSE; RADIOMETRY; SCINTISCANNING; TISSUE DISTRIBUTION;

ADOLESCENT; BODY BURDEN; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; METABOLIC CLEARANCE RATE; MONOIODOTYROSINE; ORGAN SPECIFICITY; PILOT PROJECTS; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 34250316216     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0303-3     Document Type: Article

References (23)

1. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514(2):291-302.
2. Shennan DB, Thomson J, Barber MC, Travers MT. Functional and molecular characteristics of system L in human breast cancer cells. Biochim Biophys Acta. 2003;1611(1-2):81-90.
3. Ohkame H, Masuda H, Ishii Y, Kanai Y. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol 2001;78(4):265-71; discussion 71-2.
4. Lahoutte T, Caveliers V, Camargo SM, Franca R, Ramadan T, Veljkovic E, et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med. 2004;45(9):1591-6.
5. Lahoutte T, Mertens J, Caveliers V, Franken PR, Everaert H, Bossuyt A. Comparative biodistribution of iodinated amino acids in rats: selection of the optimal analog for oncologic imaging outside the brain. J Nucl Med 2003;44(9):1489-94.
6. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 2003;33(2):148-62.
7. Kim CK, Alavi JB, Alavi A, Reivich M. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 1991;10(1):85-91.
8. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78(5):1098-106.
9. Fischman AJ, Thornton AF, Frosch MP, Swearinger B, Gonzalez RG, Alpert NM. FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma. J Nucl Med 1997;38(7):1027-9.
10. Dethy S, Goldman S, Blecic S, Luxen A, Levivier M, Hildebrand J. Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma. J Nucl Med. 1994;35(7):1162-6.
11. Ogawa T, Hatazawa J, Inugami A, Murakami M, Fujita H, Shimosegawa E, et al. Carbon-11-methionine PET evaluation of intracerebral hematoma: distinguishing neoplastic from non-neoplastic hematoma. J Nucl Med 1995;36(12):2175-9.
12. Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996;23(10):1345-53.
13. 99mTc-HMPAO SPECT. Ann Nucl Med 2002;16(3):207-11.
14. Sasaki M, Ichiya Y, Kuwabara Y, Yoshida T, Inoue T, Morioka T, et al. Hyperperfusion and hypermetabolism in brain radiation necrosis with epileptic activity. J Nucl Med 1996;37(7):1174-6.
15. Mertens J, Gysemans M. Cu1+ assisted nucleophilic exchange radiohalogenation: application and mechanistic approach. New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control 1991:53-65.
16. De Geeter F, Franken PR, Defrise M, Andries H, Saelens E, Bossuyt A. Optimal collimator choice for sequential iodine-123 and technetium-99m imaging. Eur J Nucl Med 1996;23(7):768-74.
17. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46(6):1023-7.
18. 123I]iodo-L-alpha-methyl tyrosine and single photon emission tomography. Nucl Med Commun 2003;24(6):633-41.
19. 123I-iodo-alpha- methyltyrosine. Eur J Nucl Med 1997;24(9):1162-6.
20. 123I]iodo-L-phenylalanine for routine brain tumour imaging. Nucl Med Commun 2002;23(2):121-30.
21. Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BF, et al. Clinical value of iodine-123-alpha-methyl-L-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 2002;20(2):396-404.
22. 123/125I-labelled 2-iodo-L-phenylalanine and 2-iodo-D-phenylalanine: comparative uptake in various tumour types and biodistribution in mice. Eur J Nucl Med Mol Imaging 2006;33(8):919-27.
23. 18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 2006;33(8):932-9.